⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8998513 | 0.71 | — | — | |
| Methyl Alcohol SCHEMBL28243349 | 0.69 | ALDH1A1 (0.32) | — | |
| SCHEMBL20528895 | 0.67 | FDPS (0.33) | — | |
| SCHEMBL10522666 | 0.67 | — | — | |
| SCHEMBL36478 | 0.67 | — | — | |
| SCHEMBL1243986 | 0.67 | — | — | |
| SCHEMBL780071 | 0.67 | — | — | |
| SCHEMBL779378 | 0.65 | HSD17B10 (0.32) | — | |
| SCHEMBL16296066 | 0.65 | TSHR (0.36) | — | |
| Peroxymonophosphate SCHEMBL5152278 | 0.63 | TRPA1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996040155-A1 | USE OF SPECIFIC ACPA DERIVATIVE (NPC-17742) FOR THE TREATMENT OF ISCHEMIA | THE JOHNS HOPKINS UNIVERSITY (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0639197-B1 | EXCITATORY AMINO ACID ANTAGONISTS | GUILFORD PHARM INC (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0639197-A1 | EXCITATORY AMINO ACID ANTAGONISTS. | GUILFORD PHARM INC (US) | 1995-02-22 | — | — | EP | disclosed |
| EP-0639197-A4 | EXCITATORY AMINO ACID ANTAGONISTS. | GUILFORD PHARM INC (US) | 1994-02-21 | — | — | EP | disclosed |
| US-5256814-A | Anticonvulsant, analgesic, cognition activator | SCIOS NOVA INC. (US) | 1993-10-26 | — | — | US | disclosed |
| WO-1992010099-A1 | EXCITATORY AMINO ACID ANTAGONISTS | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |